Sylvester Comprehensive Cancer Center, University of Miami | Strategic Alliance Partners

April 12, 2018

There are multiple therapeutic options in development for the treatment of patients with HER2-positive breast cancer, further adding to the regimens available, explains Frances Valdes-Albini, MD.

April 12, 2018

Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the FDA approval of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

April 09, 2018

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses side effects of ovarian suppression in patients with breast cancer.

April 05, 2018

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the benefit of pertuzumab (Perjeta) plus trastuzumab (Herceptin) for patients with HER2-positive breast cancer.

April 05, 2018

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the updated data from the TEXT and SOFT clinical trials in premenopausal women with hormone-receptor positive (HR+) breast cancer.

March 30, 2018

Gilberto Lopes Jr, MD, a medical director for International Programs at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses steroid side effects in lung cancer management.

March 23, 2018

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the use of CDK 4/6 inhibitors in older patients with estrogen receptor-positive breast cancer.

March 21, 2018

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses advancements in adjuvant HER2-positive breast cancer.

May 28, 2017

Jonathan C. Trent, MD, PhD, discusses Sylvester Comprehensive Cancer Center’s ongoing efforts to advance the precision medicine process to improve patient care.

March 22, 2017

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the future of adjuvant treatment in HER2-positive breast cancer.

March 21, 2017

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses the status of a phase II trial investigating concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in patients with advanced alveolar soft part sarcoma and other soft tissue sarcomas.

December 23, 2016

Molecular testing is done for patients with non–small cell lung cancer to determine what genetic abnormalities are present. If a common-enough mutation is detected—such as EGFR or ALK—then patients are able to receive a targeted agent matched to that driver.

December 01, 2016

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the challenges researchers must overcome in patients with non-driver adenocarcinoma.

June 20, 2016

Jonathan C. Trent, MD, PhD, discusses notable findings in sarcomas that emerged at the 2016 ASCO Annual Meeting, as well as what lies ahead for the field of sarcomas.

February 15, 2016

Epigenetic therapy has emerged as a novel approach, not necessarily by killing cancer cells, but perhaps by altering the network of chemical changes that affect the DNA/chromatin within cancer cells.

December 02, 2015

Jonathan C. Trent, MD, associate director for Clinical Research, director of the Sarcoma Medical Research Program at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, discusses sequencing trabectedin (Yondelis) for patients with soft tissue sarcoma.

November 24, 2015

Mohammad Jahanzeb, MD, discusses emerging strategies in the adjuvant treatment of patients with HER2-positive breast cancer.

October 16, 2015

Determining the best course of treatment for sarcomas of the bone and soft tissues is a complex process.

October 09, 2015

Mohammad Jahanzeb, MD, discusses therapeutic agents that may fit into the adjuvant setting treatment paradigm for HER2-positive breast cancer, the increasing importance of genomic testing, and individualized treatments as multiple agents emerge.

August 04, 2015

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology Oncology, University of Miami's Miller School of Medicine, discusses potential mechanisms for overcoming HER2 resistance in breast cancer.